Curatis Holding AG (SWX: CURN)
Salud · Farmacéuticas · CH
16,00 CHF
-4,76 % hoy · +30,6 % 1 año
Curatis Holding AG (SWX: CURN) opera en la industria de farmacéuticas dentro del sector salud. Su valor en bolsa es de 101,48 M $ y tiene 9 empleados.
En los últimos doce meses la acción ha subido un 30,6 % y ha cotizado entre 11,05 y 27,90.
Tweenvest puntúa a Curatis Holding AG en cuatro factores: calidad 77/100, valor 59/100. Su punto más fuerte es calidad.
Evolución de la cotización de CURN
Cifras clave
- Capitalización
- 101,48 M $
- Ingresos (últ. 12 m)
- 16,70 M $
- PER
- -78,47
- BPA
- -0,13
- Rent. por dividendo
- —
- Beta (5 años)
- -0,64
- Máximo 52 semanas
- 27,90 CHF
- Mínimo 52 semanas
- 11,05 CHF
- Volumen medio (3 m)
- —
- Acciones en circulación
- 5,32 M
- Empleados
- 9
- Próximos resultados
- —
Sobre Curatis Holding AG
Curatis Holding AG specializes in the entire lifecycle of pharmaceutical products, including the procurement, advancement, and market release of medications specifically designed for the diagnosis, prevention, and management of rare and specialized medical conditions. The company's extensive product offerings span a broad array of therapeutic areas. These encompass treatments for antiplatelet conditions, metastatic hormone receptor-positive breast cancer, anti-arrhythmic disorders, nasal oil applications, Wilson's disease, antidotes for cyanide poisoning and digoxin toxicity, antihypotensive agents, therapies for bladder pain syndrome/interstitial cystitis, antibiotics, diagnostic tools for ophthalmology, antivirals, ophthalmic/antibiotic combinations, gentamycin collagen sponges, solutions for benign prostatic hyperplasia, immunomodulators, treatments for epilepsy and essential tremor, thyreostatics, therapies for hereditary tyrosinemia type 1, gastroenterological products, additional immunomodulators and thyreostatics, tranquilizers, Helicobacter pylori tests, phosphate binders, specialized nutritional support for dialysis patients, dermatological corticosteroids, antidotes for lead and mercury poisoning, corticostimulants, anti-fog agents, treatments for chorea associated with Huntington's disease, and antiepileptics. In addition to its commercialized portfolio, Curatis is actively engaged in developing new pharmaceutical compounds. Its pipeline includes C-PTBE-01, currently in Phase IIb clinical trials for treating peritumoral brain edema in pediatric patients; C-AM-01, undergoing Phase IIa trials for preventing severe migraine with aura; and C-MOH-01, also in Phase IIa for the treatment and prevention of medication overuse headache. Furthermore, KIN001 is in Phase I clinical trials, targeting rare inflammatory and fibrotic diseases. The company maintains its headquarters in Liestal, Switzerland.
- ISIN
- CH1330780979
- Fundada en
- 2002
- Cotiza desde
- 16 abr 1999
- Bolsa
- SIX Swiss Exchange
- Divisa
- CHF
Otras empresas de farmacéuticas
| Empresa | Capitalización | Precio | Día |
|---|---|---|---|
| Journey Medical CorporationNasdaqCM: DERM | 104,15 M $ | 3,69 $ | -5,38 % |
| Organigram Global Inc.TSX: OGI | 102,49 M $ | 1,04 CA$ | -11,86 % |
| Semnur Pharmaceuticals, Inc.OTCPK: SMNR | 102,32 M $ | 0,47 $ | +42,42 % |
| Retension Pharmaceuticals, Inc.NasdaqCM: RTSN | 102,23 M $ | 12,27 $ | +0,16 % |
| LENZ Therapeutics, Inc.NasdaqGS: LENZ | 100,86 M $ | 3,21 $ | -7,76 % |
| Themis Medicare LimitedBSE: 530199 | 99,14 M $ | 101,50 Rs | -0,61 % |
| The Jordanian Pharmaceutical Manufacturing Company - Public Shareholding CompanyASE: JPHM | 98,68 M $ | 1,54 JD | 0,00 % |
| SYN-TECH Chem. & Pharm. Co., Ltd.TPEX: 1777 | 97,84 M $ | 72,40 NT$ | -1,90 % |